Ironwood Pharmaceuticals, Inc. (IRWD)
USD 1.24
(-7.84%)
USD 1.24
(-7.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 471.07 Million USD | -57.2% |
| 2022 | 1.1 Billion USD | -2.34% |
| 2021 | 1.12 Billion USD | 101.51% |
| 2020 | 559.23 Million USD | 38.86% |
| 2019 | 402.74 Million USD | 21.29% |
| 2018 | 332.05 Million USD | -45.18% |
| 2017 | 605.67 Million USD | -14.67% |
| 2016 | 709.82 Million USD | 14.65% |
| 2015 | 619.12 Million USD | 85.64% |
| 2014 | 333.51 Million USD | 19.55% |
| 2013 | 278.96 Million USD | 21.34% |
| 2012 | 229.9 Million USD | 10.02% |
| 2011 | 208.97 Million USD | -30.66% |
| 2010 | 301.36 Million USD | 85.51% |
| 2009 | 162.45 Million USD | 15.44% |
| 2008 | 140.72 Million USD | 3.54% |
| 2007 | 135.9 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 438.81 Million USD | -6.85% |
| 2024 Q2 | 395.62 Million USD | -9.84% |
| 2023 Q4 | 471.07 Million USD | -10.11% |
| 2023 Q3 | 524.06 Million USD | -13.12% |
| 2023 Q2 | 603.22 Million USD | -47.79% |
| 2023 Q1 | 1.15 Billion USD | 4.98% |
| 2023 FY | 471.07 Million USD | -57.2% |
| 2022 Q3 | 1.04 Billion USD | 6.63% |
| 2022 Q4 | 1.1 Billion USD | 5.78% |
| 2022 FY | 1.1 Billion USD | -2.34% |
| 2022 Q1 | 1.08 Billion USD | -3.86% |
| 2022 Q2 | 975.69 Million USD | -9.94% |
| 2021 Q3 | 1.07 Billion USD | 7.16% |
| 2021 Q1 | 599.34 Million USD | 7.17% |
| 2021 FY | 1.12 Billion USD | 101.51% |
| 2021 Q2 | 1 Billion USD | 68.05% |
| 2021 Q4 | 1.12 Billion USD | 4.41% |
| 2020 Q4 | 559.23 Million USD | 13.59% |
| 2020 FY | 559.23 Million USD | 38.86% |
| 2020 Q1 | 404 Million USD | 0.31% |
| 2020 Q2 | 443.53 Million USD | 9.79% |
| 2020 Q3 | 492.32 Million USD | 11.0% |
| 2019 FY | 402.74 Million USD | 21.29% |
| 2019 Q2 | 315.72 Million USD | -13.15% |
| 2019 Q3 | 334.34 Million USD | 5.9% |
| 2019 Q4 | 402.74 Million USD | 20.46% |
| 2019 Q1 | 363.53 Million USD | 9.48% |
| 2018 Q4 | 332.05 Million USD | -20.31% |
| 2018 FY | 332.05 Million USD | -45.18% |
| 2018 Q3 | 416.65 Million USD | -32.6% |
| 2018 Q2 | 618.21 Million USD | 8.25% |
| 2018 Q1 | 571.09 Million USD | -5.71% |
| 2017 Q2 | 705.07 Million USD | 0.54% |
| 2017 FY | 605.67 Million USD | -14.67% |
| 2017 Q3 | 625.08 Million USD | -11.35% |
| 2017 Q4 | 605.67 Million USD | -3.11% |
| 2017 Q1 | 701.31 Million USD | -1.2% |
| 2016 FY | 709.82 Million USD | 14.65% |
| 2016 Q3 | 731.97 Million USD | 4.54% |
| 2016 Q4 | 709.82 Million USD | -3.03% |
| 2016 Q1 | 603.32 Million USD | -2.55% |
| 2016 Q2 | 700.2 Million USD | 16.06% |
| 2015 Q3 | 613.42 Million USD | -6.2% |
| 2015 Q4 | 619.12 Million USD | 0.93% |
| 2015 Q1 | 305.52 Million USD | -8.39% |
| 2015 FY | 619.12 Million USD | 85.64% |
| 2015 Q2 | 653.94 Million USD | 114.04% |
| 2014 Q4 | 333.51 Million USD | -3.66% |
| 2014 Q1 | 418.87 Million USD | 50.15% |
| 2014 Q2 | 371.06 Million USD | -11.41% |
| 2014 Q3 | 346.16 Million USD | -6.71% |
| 2014 FY | 333.51 Million USD | 19.55% |
| 2013 Q1 | 325.09 Million USD | 41.4% |
| 2013 Q4 | 278.96 Million USD | -14.39% |
| 2013 Q3 | 325.84 Million USD | -15.15% |
| 2013 Q2 | 384.03 Million USD | 18.13% |
| 2013 FY | 278.96 Million USD | 21.34% |
| 2012 Q2 | 208.66 Million USD | -16.26% |
| 2012 Q1 | 249.17 Million USD | 19.24% |
| 2012 Q4 | 229.9 Million USD | -6.74% |
| 2012 Q3 | 246.51 Million USD | 18.14% |
| 2012 FY | 229.9 Million USD | 10.02% |
| 2011 Q4 | 208.97 Million USD | -4.79% |
| 2011 Q2 | 249.72 Million USD | -8.2% |
| 2011 Q1 | 272.02 Million USD | -9.74% |
| 2011 FY | 208.97 Million USD | -30.66% |
| 2011 Q3 | 219.48 Million USD | -12.11% |
| 2010 FY | 301.36 Million USD | 85.51% |
| 2010 Q4 | 301.36 Million USD | -1.03% |
| 2010 Q3 | 304.5 Million USD | -5.46% |
| 2010 Q2 | 322.08 Million USD | -4.75% |
| 2010 Q1 | 338.13 Million USD | 108.14% |
| 2009 Q4 | 162.45 Million USD | 2.27% |
| 2009 Q3 | 158.84 Million USD | 0.0% |
| 2009 FY | 162.45 Million USD | 15.44% |
| 2008 Q4 | 140.72 Million USD | 0.0% |
| 2008 FY | 140.72 Million USD | 3.54% |
| 2007 FY | 135.9 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -610.565% |
| Safety Shot Inc | 12.7 Million USD | -3606.557% |
| Bright Green Corporation | 17.4 Million USD | -2606.842% |
| Embecta Corp. | 1.21 Billion USD | 61.209% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 47.914% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -720.427% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 58.797% |
| Dynavax Technologies Corporation | 997.09 Million USD | 52.756% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -128.903% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 35.318% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 70.079% |
| PainReform Ltd. | 9.93 Million USD | -4643.938% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1622.579% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -1622.579% |
| SCYNEXIS, Inc. | 128.41 Million USD | -266.845% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1936.891% |
| Journey Medical Corporation | 76.84 Million USD | -512.985% |
| Alpha Teknova, Inc. | 128.58 Million USD | -266.346% |
| Procaps Group, S.A. | 460.18 Million USD | -2.366% |
| Theratechnologies Inc. | 77.76 Million USD | -505.734% |
| Harrow Health, Inc. | 311.75 Million USD | -51.104% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -3063.05% |
| Biofrontera Inc. | 27.93 Million USD | -1586.499% |
| DURECT Corporation | 45.18 Million USD | -942.451% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 66.566% |
| Cronos Group Inc. | 1.13 Billion USD | 58.468% |
| OptiNose, Inc. | 107.72 Million USD | -337.276% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -741.969% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1943.955% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -2.402% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -3852.559% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -476.052% |
| Radius Health, Inc. | 1.71 Billion USD | 72.547% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -784.029% |
| ProPhase Labs, Inc. | 91.92 Million USD | -412.442% |
| Phibro Animal Health Corporation | 982.18 Million USD | 52.038% |
| Procaps Group S.A. | 460.18 Million USD | -2.366% |
| Alvotech | 950.09 Million USD | 50.418% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -987.702% |
| Viatris Inc. | 47.68 Billion USD | 99.012% |
| Rockwell Medical, Inc. | 52.17 Million USD | -802.906% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -298.893% |
| SIGA Technologies, Inc. | 254.83 Million USD | -84.853% |
| Tilray Brands, Inc. | 4.33 Billion USD | 89.134% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -72.112% |
| Shineco, Inc. | 84.17 Million USD | -459.606% |
| PetIQ, Inc. | 868.22 Million USD | 45.743% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -5482.617% |
| Incannex Healthcare Limited | 17.04 Million USD | -2663.378% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 85.512% |
| Alimera Sciences, Inc. | 153.52 Million USD | -206.84% |
| Silver Spike Investment Corp. | 88.57 Million USD | -431.828% |
| Assertio Holdings, Inc. | 286.41 Million USD | -64.47% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -7814.884% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -1293.881% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -1407.771% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -3455.929% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -80.401% |
| Hempacco Co., Inc. | 18.04 Million USD | -2510.824% |
| Talphera, Inc. | 20.39 Million USD | -2209.747% |
| Alvotech | 950.09 Million USD | 50.418% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -15.982% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 71.47% |
| Currenc Group, Inc. | 141.49 Million USD | -232.936% |
| Kamada Ltd. | 351.96 Million USD | -33.839% |
| Indivior PLC | 1.95 Billion USD | 75.858% |
| Evoke Pharma, Inc. | 7.06 Million USD | -6564.355% |
| Flora Growth Corp. | 23.62 Million USD | -1893.875% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -3455.929% |
| Evolus, Inc. | 188.99 Million USD | -149.248% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 63.191% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 68.863% |
| Akanda Corp. | 8.83 Million USD | -5228.884% |